Table 4 Representative nanomedicine targets and design of HMs
Targets | Carrier | Drug | Ind. | Outcome | References |
|---|---|---|---|---|---|
CD19 | Liposome | DOX | ALL | Significantly prolonged the survival of mice | [205] |
LNP | C61 | ALL | Consistently caused apoptosis in B-precursor ALL cells | [58] | |
Au NPs | NB | ALL | Proved superior cytotoxic effect against CCRF-SB cells | [206] | |
CD3 | Gelatin NPs | ALL | Significantly increased cell absorption and internalization | [207] | |
B220 | MSN | DNR | AML | Efficiently incorporated into and preferentially kill LSCs | [209] |
CD117 | CPSNPs | ICG | CML | In vivo efficacy of PDT was dramatically enhanced | [210] |
CD123 | PMBN | PTX/GA-A | AML | Increased anti proliferation of cells | [211] |
CdTe QDs | DNR | MDS | Effectively inhibited the tumor growth of MDS-bearing nude mice | [216] | |
IL-1RAP | Cas9 RNP | MSCM-NF | AML | Reduced LSC colony-forming capacity and leukemic burden | [212] |
CD71 | Fn | Arsenic | AML | Exerted strong antileukemia effects in diverse xenograft models | [202] |
PTK7 | MS2 | Porphyrins | AML | Killed Jurkat cells selectively even when mixed with erythrocytes | [204] |
CXCR4 | Micelle | Peptide E5 | AML | Significantly inhibited the engraftment of leukemic cells in spleen and BM | [213] |
CD44 | PLGA | PTL | AML | Improved the bioavailability and selective targeting of leukemic cells | [64] |
FA | CS | 6-MP | ALL | Significantly elevated tumor intracellular drug release | [203] |
CD40 | PLGA | MTV | ALL | Significantly reduced tumor volume with increased caspase-3 activity | [231] |
CD20 | PLGA | AZD-2014 | Lyn | Significantly improved efficacy of AZD-2014 against NHL cells | [220] |
CD22 | NK-92MI | Sialyl Lewis X | Lyn | Exhibited significantly enhanced tumor cell binding and killing | [232] |
CD38 | PBCL | S3I-1757 | MM | Significantly reduced the tumor size by fourfold compared to S3I-NP | [227] |
PDGFR-β | PLA | PTX | MM | Simultaneous clearance of CAF cells and MM tumor cells | [199] |